Impacts of a Ketogenic Diet on Non-Motor Symptoms in Parkinson’s Disease

Background: Parkinson’s Disease (PD)

• Definition
  • Progressive neurodegenerative disorder characterised by both motor and non-motor manifestations.
• Epidemiology & Projected Growth
  • Current U.S. prevalence (2010): $680\,000$ individuals aged $\ge 45\,\text{y}$.
  • Projected U.S. prevalence (2030): $1.2\,\text{million+}$.
  • Global cases: $6.3\,\text{million}$ (2015) (\rightarrow) $12.9\,\text{million}$ (2040).
• Symptom Clusters
  • Motor: rigidity, tremor, bradykinesia, postural instability.
  • Non-motor: cognitive decline, depression, anxiety, sleep disturbances, autonomic dysfunction.
• Clinical Imperative
  • Rapidly rising prevalence demands interventions that improve quality of life—especially non-motor domains often less responsive to standard dopaminergic therapy.

Ketogenic Diet (KD) Primer

• Core Nutritional Philosophy
  • Very-low-carbohydrate ((<!10\%) kcal), high-fat ((\approx!75!+\%) kcal), moderate-protein diet.
  • Physiological shift: primary energy substrate switches from glucose to hepatic ketone bodies ((\beta)-hydroxybutyrate, acetoacetate, acetone).
• Proposed Neurobiological Mechanisms Relevant to PD
  • Enhanced mitochondrial efficiency & ATP generation.
  • Reduced oxidative stress and glutamate excitotoxicity.
  • Modulation of gut–brain axis and neuroinflammation.
  • Potential up-regulation of neurotrophic factors.

Common Clinical Rating Tools Appearing in All Studies

• Unified Parkinson’s Disease Rating Scale / MDS-UPDRS
  • Parts 1–4, each scored $0$ (no impairment) to $4$ (severe).
  • Part 1: non-motor experiences of daily living.
  • Part 2: motor experiences of daily living.
  • Part 3: motor examination.
  • Part 4: motor complications.
• Hoehn & Yahr (H\&Y) Staging Scale
  • $1$ (unilateral, mild) to $5$ (wheelchair/bed-ridden).

Study 1: Acute KD Effects on PD Symptoms

• Design & Sample
  • $n=16$; mean age $64.5\,\text{y}$; H\&Y $1!–!4$.
  • Duration: $12\,\text{weeks}$; single-arm KD only.
• Dietary Prescription
  • Energy distribution: $78\%$ fat, $17\%$ protein, $3!–!4\%$ CHO.
  • Dietary adherence logged via MyFitnessPal or written journals.
• Biomarkers & Outcome Measures
  • Daily blood ketones via Keto-Mojo meter.
  • MDS-UPDRS Parts 1–4 analysed pre/post.
• Key Findings
  • $14/16$ participants maintained nutritional ketosis.
  • Significant improvement exclusively in Part 1 (non-motor) for all participants; magnitude larger in ketosis-maintainers.
  • Parts 2–4 (motor) showed improvements but not statistically significant.
• Implications
  • Acute KD can meaningfully alleviate non-motor symptom burden; effect appears ketosis-dependent.

Study 2: KD Supplemented with Medium-Chain Triglyceride (MCT) Oil

• Design & Sample
  • $n=16$ initial; mean age $67.2\,\text{y}$; H\&Y $2!–!4$.
  • Inpatient week $1$: randomised to KD vs standard diet (SD); weeks $2$–$3$ outpatient KD for all.
  • $1$ withdrawal ➔ $n=15$ completers.
• Inpatient Diet Composition
  • KD: $80\%$ fat (of which $25\%$ fat = MCT), $10!–!15\%$ protein, $5!–!10\%$ CHO.
  • SD: $35\%$ fat, $15\%$ protein, $50!–!55\%$ CHO.
• Tracking
  • Repeated $24\,\text{h}$ dietary recalls, exit feasibility survey.
• Outcomes
  • MDS-UPDRS Parts 1–3 and “time” domain (duration in OFF state).
  • Feasibility: $12/15$ participants “somewhat to very likely” to continue KD long-term.
  • Symptom change: within-group improvements in both arms; KD significant for Parts 1 & 2, SD significant only for Part 2; no significant between-group difference.
• Take-Home
  • KD (with MCT) is practical and acceptable in short term; symptomatic gains modest and not clearly superior to SD under study conditions.

Study 3: KD vs Low-Fat (LF) Diet – Safety & Efficacy Trial

• Design & Sample
  • $n=47$ randomised: KD $=24$, LF $=23$; mean age $63\,\text{y}$; BMI >18.5.
  • Withdrawals: KD $-6$, LF $-3$ ➔ completers KD $=18$, LF $=20$.
  • Duration: $8\,\text{weeks}$ outpatient.
• Diet Macros (daily means)
  • KD: $152\,\text{g}$ fat, $75\,\text{g}$ protein, $16\,\text{g}$ CHO.
  • LF: $42\,\text{g}$ fat, $25\,\text{g}$ protein, $246\,\text{g}$ CHO.
  • Menu checklists + finger-prick glucose/ketone monitoring ensured adherence.
• Metabolic Outcomes (weekly bedtime averages)
  • Blood glucose: KD $5.70\,\text{mmol!/L}$ vs LF $6.28\,\text{mmol!/L}$ (significant).
  • Blood ketones: KD $1.15\,\text{mmol!/L}$ vs LF $0.16\,\text{mmol!/L}$ (significant).
• Clinical Outcomes (MDS-UPDRS Parts 1–4)
  • Both groups improved from baseline.
  • KD superior in Parts 1, 2, 4 (non-motor daily living, motor daily living, motor complications).
  • LF superior in Part 3 (motor examination).
  • Only statistically significant domain: non-motor daily living (Part 1) favouring KD.
• Conclusions
  • KD safely induces nutritional ketosis with favourable glycaemic profile.
  • Demonstrates targeted benefit for non-motor PD symptoms versus LF diet.

Integrated Synthesis Across Studies

• Repeated Pattern
  • All three investigations converge on significant relief of non-motor symptoms under KD, particularly when ketosis ((\beta)-HB >0.5\,\text{mmol!/L}) is sustained.
• Motor Domains
  • Trend toward improvement but inconsistency across trials; superiority vs comparator diets remains inconclusive.
• Feasibility & Adherence
  • High short-term adherence ((\ge85\%) completion) despite restrictive macros; majority willing to maintain diet post-study.
• Biochemical Correlates
  • Lower glucose and higher ketones align with symptom reductions, supporting metabolic mechanism hypothesis.

Ethical, Practical & Philosophical Implications

• Patient Autonomy
  • KD empowers individuals with dietary agency, complementing pharmacotherapy.
• Quality of Life vs Rigor
  • Restrictive eating may impose psychosocial burden; balance between clinical benefit and lifestyle sustainability necessary.
• Healthcare Equity
  • KD foods (e.g., high-quality fats, MCT oil) can be cost-prohibitive; warrants policy consideration for widespread adoption.

Limitations Noted by Authors

• Limited or absent true control groups in two studies; causal inference weakened.
• Small sample sizes (max $n=47$) reduce statistical power.
• Short durations ((<!12\,\text{weeks})) limit assessment of long-term efficacy & safety (e.g., lipid profile changes).
• Participant withdrawals and data imputation potentially bias outcomes.
• Self-reported dietary logs susceptible to under/over-reporting.

Future Research Directions

• Larger, multi-centre RCTs comparing KD with multiple dietary paradigms (Mediterranean, plant-based, modified Atkins, etc.).
• Longitudinal studies ((\ge12\,\text{months})) for durability, disease progression markers, and cardiometabolic safety.
• Mechanistic trials measuring CSF ketone penetration, neuroinflammatory markers, and gut microbiome shifts in PD.
• Customised KD protocols enhancing palatability & cultural adaptability to improve outpatient adherence.

Quick Summary for Exam Review

• PD non-motor symptoms (cognition, mood) remain challenging with standard care; KD shows reproducible benefit.
• Symptom scales consistently identify Part 1 (non-motor) as the domain of significant KD impact.
• Nutritional ketosis (blood $\beta)-HB$\approx1\,\text{mmol!/L}$$) appears threshold for clinical effect.
• Motor symptom data mixed; more evidence needed.
• Feasibility surveys favourable, but long-term sustainability & equity require further study.

References (As Listed in Presentation)

• Full citation list provided by Chelsea Scott; includes foundational PD epidemiology papers, original KD mechanisms literature, and the three primary clinical studies summarised above.